MYH10 Combines with MYH9 to Recruit USP45 by Deubiquitinating Snail and Promotes Serous Ovarian Cancer Carcinogenesis, Progression, and Cisplatin Resistance
Sign Up to like & getrecommendations! Published in 2023 at "Advanced Science"
DOI: 10.1002/advs.202203423
Abstract: The poor prognosis of serous ovarian cancer (SOC) is due to its high invasive capacity and cisplatin resistance of SOC cells, whereas the molecular mechanisms remain poorly understood. In the present study, the expression and… read more here.
Keywords: progression cisplatin; cisplatin; myh10; cisplatin resistance ... See more keywords
LINC01140 inhibits nonsmall cell lung cancer progression and cisplatin resistance through the miR‐4742‐5p/TACC1 axis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Biochemical and Molecular Toxicology"
DOI: 10.1002/jbt.23048
Abstract: Recent studies show that lncRNAs participate in drug resistance and nonsmall cell lung cancer (NSCLC) progression. This study aimed to study the roles and mechanisms of long intergenic nonprotein coding RNA 01140 (LINC01140) in regulating… read more here.
Keywords: mir 4742; mir; linc01140; cisplatin resistance ... See more keywords
Long noncoding RNA OIP5‐AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR‐340‐5p
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.28244
Abstract: The abnormal expression of long noncoding RNAs (lncRNAs) plays an important role in the regulation of human cancer progression and drug resistance. The lncRNA OPI5‐AS1 is a crucial regulator in some cancers; however, its role… read more here.
Keywords: oip5 as1; osteosarcoma; pi3k akt; resistance ... See more keywords
FOXC2 promotes epithelial–mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3697-2
Abstract: PurposePlatinum-based drugs, particularly cisplatin (DDP), are used in the treatment of non-small cell lung cancer (NSCLC). However, development of drug resistance remains the major therapeutic barrier in NSCLC.MethodsThe potential cisplatin resistance-related genes were identified from… read more here.
Keywords: cisplatin; nsclc cells; resistance; non small ... See more keywords
CircUBAP2 promotes SEMA6D expression to enhance the cisplatin resistance in osteosarcoma through sponging miR-506-3p by activating Wnt/β-catenin signaling pathway
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Molecular Histology"
DOI: 10.1007/s10735-020-09883-8
Abstract: The occurrence of chemo-resistance is an essential reason for the high morbidity of osteosarcoma (OS) patients. Circular RNAs (circRNAs) have been involved in the regulation of chemo-resistance in cancers. Semaphorins 6D (SEMA6D) is abnormally expressed… read more here.
Keywords: mir 506; resistance; cisplatin resistance; wnt catenin ... See more keywords
Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling
Sign Up to like & getrecommendations! Published in 2019 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2019.08.057
Abstract: Background Cisplatin resistance remains a major clinical obstacle to the successful treatment of non-small cell lung cancer (NSCLC). Scribble contributes to ROS-induced inflammation and cisplatin-elevated toxic reactive oxygen species (ROS) promotes cell death. However, it… read more here.
Keywords: chemotherapy; nox2 ros; cisplatin; ros nrf2 ... See more keywords
Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2017.02.016
Abstract: The structure of alpha-napthoflavone (ANF), a potent inhibitor of CYP1A1 and CYP1B1, mimics the structure of chalcones. Two potent CYP1B1 inhibitors 7k (DMU2105) and 6j (DMU2139) have been identified from two series of synthetic pyridylchalcones.… read more here.
Keywords: cyp1b1; cyp1b1 inhibitors; ic50 values; cisplatin resistance ... See more keywords
Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2017.05.056
Abstract: Two platinum(IV) complexes were designed and prepared by conjugation of cisplatin and oxaliplatin units with a DNA-damaging agent, chlorambucil, respectively. By taking a joint action to enhance the damage of DNA, the conjugates displayed potent… read more here.
Keywords: platinum; cisplatin; resistance; joint action ... See more keywords
NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia research"
DOI: 10.1016/j.leukres.2021.106708
Abstract: BACKGROUND The aberrant expression of serine/threonine kinase 33 (STK33) has been implicated in cancers. However, its clinical significance and biological functions in diffuse large B cell lymphoma (DLBCL) remain largely unknown. In the present investigation,… read more here.
Keywords: cell; cisplatin; expression; resistance ... See more keywords
TIPE2 suppressed cisplatin resistance by inducing autophagy via mTOR signalling pathway.
Sign Up to like & getrecommendations! Published in 2020 at "Experimental and molecular pathology"
DOI: 10.1016/j.yexmp.2020.104367
Abstract: Tumour necrosis factor-α-induced protein-8-like-2 (TIPE2) has been associated with the progression of numerous cancers. Cisplatin, as a classical chemotherapy strategy for cancers, has been applied in non-small-cell lung cancer (NSCLC) clinical therapy but bears the… read more here.
Keywords: tipe2; cisplatin; mtor; cisplatin resistance ... See more keywords
Enhanced expression of lncRNA ZXF1 promotes cisplatin resistance in lung cancer cell via MAPK axis.
Sign Up to like & getrecommendations! Published in 2020 at "Experimental and molecular pathology"
DOI: 10.1016/j.yexmp.2020.104484
Abstract: Long non-coding RNA (lncRNA) ZXF1 has recently been associated with the poor prognosis of lung cancer by promoting metastasis. However, little is known regarding the role of ZXF1 in lung cancer treatment and the underlying… read more here.
Keywords: cancer; cisplatin resistance; lncrna zxf1; lung cancer ... See more keywords